Vaishali Pharma Peer Comparison

NSE: VAISHALI

₹8.31

₹-0.02 (-0.24%)

As on 28-Aug-2026IST

Market cap

₹112 Cr

Revenue (TTM)

₹108 Cr

P/E Ratio

26.4

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	112	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	108	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	4.24	414.00	288.22	-371.81	387.35
Net Margin (%)	3.80	11.23	14.79	-3.93	26.01
RoE (%)	6.22	8.38	29.77	-3.85	25.18
Price to Earnings	26.45	78.49	103.71	--	69.57
Price-To-Book	1.57	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	107.92	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	111.49	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	103.69	2,792.00	1,485.56	8,195.15	919.25
EBITDA	4.23	772.00	450.24	1,010.13	542.56
Depreciation	0.60	226.00	50.83	857.51	37.68
EBIT	3.64	546.00	399.41	152.62	504.88
Interest	1.83	217.00	40.84	342.73	3.77
Other Income	3.57	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	5.38	463.00	371.35	-162.68	528.56
Provision for Tax	1.14	49.00	83.14	209.13	141.21
Profit after Tax	4.24	414.00	288.22	-371.81	387.35

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	68.99	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	5.98	1,712.00	202.03	5,044.14	42.40
Current Liabilities	48.30	1,622.00	835.87	4,758.28	230.82
Total Liabilities	109.84	8,100.00	1,451.43	15,513.53	1,549.26

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	7.27	5,343.00	519.60	10,211.52	1,026.85
Current Assets	112.96	2,606.00	1,681.81	7,191.66	881.27
Total Assets	109.84	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	11.66	1,859.00	393.17	4,720.27	8.18
Net Current Assets	64.67	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	770.26	12.25	99.76	15.38

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-18.04	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-0.19	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	18.49	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	0.26	-396.00	54.56	-25.99	155.52

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	4.99	4.07	26.97	6.61	20.14
ROE (%)	6.22	8.38	29.77	-3.85	25.18
ROA (%)	3.64	4.94	24.77	-2.21	21.93
EBIT Margin (%)	3.37	15.32	20.63	1.66	34.54
Net Margin (%)	3.80	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	3.08	18.37	46.65	0.78	40.90
EBIT Growth (%)	360.27	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	968.51	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	101.01	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	81.26	29.77	42.49	2.28	94.96

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	24.10	80.56	102.12	-93.01	69.57
Price / Book Value	1.41	6.38	22.27	3.64	15.55
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	28.84	43.48	66.20	32.91	49.08
Market Cap (₹ Cr)	164.13	23,064.69	0.00	29,731.27	19,988.69

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.08	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.07	0.11	0.54	0.12	0.02
Current Ratio	2.34	1.61	2.01	1.51	3.82
Quick Ratio	2.27	1.06	1.14	0.87	2.82
Interest Coverage	3.95	3.13	10.09	0.53	141.16

	Vaishali Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	47.05	16.50	26.28	23.44	24.80
Asset Turnover	0.93	0.43	1.66	0.55	0.83
Receivable days	177.19	60.36	47.59	77.05	90.06
Inventory Days	9.56	64.42	62.58	77.13	61.02
Payable days	99.12	218.94	228.78	173.49	96.06
Cash Conversion Cycle	87.63	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.